Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03.01.2024 - BOSTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) - Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief ...
Source: wallstreet-online.de